Literature DB >> 14615565

CT findings in sclerosing mesenteritis (panniculitis): spectrum of disease.

Karen M Horton1, Leo P Lawler, Elliot K Fishman.   

Abstract

Sclerosing mesenteritis is a complex inflammatory disorder of the mesentery. Although sclerosing mesenteritis is often associated with other idiopathic inflammatory disorders such as retroperitoneal fibrosis, sclerosing cholangitis, Riedel thyroiditis, and orbital pseudotumor, its exact cause is unknown. The computed tomographic (CT) appearance of sclerosing mesenteritis will vary depending on the predominant tissue component (fat, inflammation, or fibrosis). CT plays an important role in suggesting the diagnosis in the proper clinical setting and can be useful in distinguishing sclerosing mesenteritis from other mesenteric diseases with similar CT features such as carcinomatosis, carcinoid tumor, lymphoma, desmoid tumor, and mesenteric edema. Nevertheless, surgical biopsy and pathologic analysis are usually necessary to make the diagnosis. Treatment may consist of therapy with steroids, colchicine, immunosuppressive agents, or orally administered progesterone. Surgical resection is sometimes attempted for definitive therapy, although the surgical approach is often limited by vascular involvement. CT with three-dimensional volume rendering is optimal for accurate, noninvasive follow-up of sclerosing mesenteritis and of any potential complications.

Entities:  

Mesh:

Year:  2003        PMID: 14615565     DOI: 10.1148/rg.1103035010

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  56 in total

1.  Sclerosing Mesenteritis: Diverse clinical presentations and dissimilar treatment options. A case series and review of the literature.

Authors:  Konstantinos Vlachos; Fotis Archontovasilis; Evangelos Falidas; Stavros Mathioulakis; Stefanos Konstandoudakis; Constantinos Villias
Journal:  Int Arch Med       Date:  2011-06-02

Review 2.  Mesenteric panniculitis: US and CT features.

Authors:  A C van Breda Vriesman; H M Schuttevaer; E G Coerkamp; J B C M Puylaert
Journal:  Eur Radiol       Date:  2004-08-05       Impact factor: 5.315

3.  Pseudocyst formation in retroperitoneal fibrosis relapse.

Authors:  I Jansen; T R Hendriksz; E F H Van Bommel
Journal:  Br J Radiol       Date:  2010-06       Impact factor: 3.039

4.  [Post-operative sclerosing mesenteritis].

Authors:  H Frickmann; S Jungblut; N Holzknecht; M-L Hansmann; P Hanke
Journal:  Urologe A       Date:  2007-01       Impact factor: 0.639

Review 5.  Occasional finding of mesenteric lipodystrophy during laparoscopy: a difficult diagnosis.

Authors:  Nereo Vettoretto; Domenico-Roberto Diana; Roberto Poiatti; Armando Matteucci; Caterina Chioda; Maurizio Giovanetti
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

6.  Mesenteric panniculitis: various presentations and treatment regimens.

Authors:  Iyad Issa; Hassan Baydoun
Journal:  World J Gastroenterol       Date:  2009-08-14       Impact factor: 5.742

7.  High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma.

Authors:  Raghava Kashyap; Eddie Lau; Anupkumar George; John F Seymour; Stephen Lade; Rodney J Hicks; Michael S Hofman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-08       Impact factor: 9.236

8.  Multidetector-row computed tomography findings of sclerosing mesenteritis with associated diseases and its prevalence.

Authors:  Murat Canyigit; Ali Koksal; Ayca Akgoz; Taylan Kara; Murat Sarisahin; Okan Akhan
Journal:  Jpn J Radiol       Date:  2011-09-01       Impact factor: 2.374

Review 9.  Misty mesentery: a pictorial review of multidetector-row CT findings.

Authors:  A Filippone; R Cianci; F Di Fabio; M L Storto
Journal:  Radiol Med       Date:  2010-12-03       Impact factor: 3.469

Review 10.  Fibrosis and carcinoid syndrome: from causation to future therapy.

Authors:  Maralyn Druce; Andrea Rockall; Ashley B Grossman
Journal:  Nat Rev Endocrinol       Date:  2009-05       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.